Corneal targeted fenticonazole nitrate-loaded novasomes for the management of ocular candidiasis: Preparation, *in vitro* characterization, *ex vivo* and *in vivo* assessments

Sadek Ahmed, Maha M. Amin, Sarah Mohamed El-Korany and Sinar Sayed

**ABSTRACT**

The purpose of this manuscript was to develop and optimize Fenticonazole Nitrate (FTN)-loaded novasomes aiming to enhance drug corneal penetration and to improve its antifungal activity. Ethanol injection was used to formulate FTN-loaded novasomes adopting a central composite design. The researched factors were: stearic acid concentration (g%) (A), span 80: drug ratio (B) and cholesterol amount (mg) (C), and their effects on percent entrapment efficiency (EE%), particle size (PS), poly-dispersity index (PDI), zeta potential (ZP), and *in vitro* drug release after 8 hours (Q8h) were studied. Numerical optimization by Design-Expert® software was employed to select the optimum formula in respect to highest EE%, ZP (as absolute value), and Q8h >80% and lowest PS and PDI. Additional evaluation of the optimum formula was accomplished by short term stability study, effect of gamma sterilization, determination of Minimal Inhibitory Concentration and *ex vivo* corneal permeation study. The *in vivo* evaluation of the optimum formula was done to ensure its safety via *in vivo* ocular irritancy and *in vivo* corneal tolerance studies. Also, the efficacy was confirmed through *in vivo* corneal uptake study and susceptibility test. The optimum formula with the highest desirability value (0.738) showed EE% (94.31%), PS (197.05 nm), ZP (-66.95 mV) and Q8h (85.33%). It revealed to be safe, with augmented corneal permeation (527.98 µg/cm²) that leads to higher antifungal activity. The above results confirmed the validity of novasomes to improve the corneal permeation and antifungal activity of Fenticonazole Nitrate.

1. Introduction

The human’s eye is a very sensitive organ with a complex structure that can suffer from many ophthalmic diseases ranging from slight disorders like conjunctivitis to complaints that could cause blindness. Therefore, suitable medication should be selected and delivered to the distressed part (Albash et al., 2021). There are several structural and physiological obstacles throughout the eye that limit ocular absorption, such as stimulated tear formation, natural tear turnover and fast precorneal clearance. In addition, portion of the given dose could reach the systemic circulation by the nasolacrimal pathway, resulting in potential side effects (El-Sayed & Sayed, 2017). Topical eye drops are frequently used because of their simple instillation and noninvasive administration. However, serious damage in the ocular surface could result from the frequent usage of concentrated solutions (Kaur et al., 2004). Vesicular Nano-carriers are believed to overwhelm the obstacles of ophthalmic delivery and to improve the ocular regulated delivery of ophthalmic medications.
polyoxyethylene fatty acid (Mosallam et al., 2021). Many vaccines have been synthesized as novasomes (Gregoriadis, 1995; Chambers et al., 2004). Stearic acid is a saturated free fatty acid (FAA) that is used widely in formulations due to its safety (Singh et al., 2020). Cholesterol is a chief component of the plasma membrane of mammalian cells. It’s involved in many biological processes like preserving fluidity of plasma membrane and biosynthesis of bile acids, steroid hormones, and vitamin D (Xu et al., 2022). It has a critical impact on vesicle stability, loading capacity and permeability (Abdelbary et al., 2017). Span 80 is a biodegradable nonionic surface active agent derived from oleic acid and sorbitol. Surfactants have a critical effect on the structure and the properties of many vesicular systems, they also serve as penetration enhancers (Abd-Elsalam & Ibrahim, 2021).

Fungal ophthalmic diseases are considered very dangerous since that could lead to blindess (Albash et al., 2021). The increased immunocompromised population from viral infections, chemotherapy, transplantation surgeries and anti-cancers resulted in a remarkable spread in the occurrence of fungal ophthalmic infections. Recently, anti-fungal drugs are consumed separately or in combination with antibiotics and corticosteroids (Veraldi & Milani, 2008). Fenticonazole nitrate (FTN) is an antifungal imidazole compound whose mechanism of action involves preventing ergosterol production, resulting in harming the cytoplasmic membrane of the fungi (Campos et al., 2018). FTN has both fungistatic and fungicidal actions on dermatophytes, yeasts and fungi, in addition to its activity against Gram positive bacteria. FTN has a low aqueous solubility that is less than 0.10mg/mL, and this could have an undesirable consequence on its effectiveness, pharmacokinetic profiles and the development of resistance. Many techniques were formerly used to enhance its efficacy like terpesomes (Albash et al., 2021) and cerosomes (Albash et al., 2021). Terpesomes developed by Albash et al., showed small particle size, high EE %, improved corneal adhesion and greater in vivo retention compared to drug suspension (Albash et al., 2021). Cerosomes formulated by Albash et al., revealed minute particle size, acceptable zeta potential and improved safety (Albash et al., 2021).

Central composite design (CCD) is an example of response surface methodology that can be used for formulation optimization. Advantages of CCD include: require few design points, high accuracy and provide a rational amount of data for assessing the suitability of fit (Imanian & Biglari, 2022) compared to the counterpart three level full factorial design.

Specifically, the goal of this research is to develop and optimize FTN-loaded novasomes via central composite design, by studying the effect of stearic acid concentration (g%), span 80: drug ratio and cholesterol amount (mg) on percent entrapment efficiency (EE %), particle size (PS), poly-dispersity index (PDI), zeta potential (ZP), and Q8h in vitro drug release. The optimized formula was further evaluated in vitro regarding (DSC, FTIR, TEM), short term stability, MIC determination and effect of gamma sterilization. In addition, ex vivo corneal permeation study and in vivo evaluation of the optimum formula to ensure its safety via in vivo ocular irritancy and corneal tolerance studies were assessed. Finally, the efficacy of the optimum FTN-loaded formula was confirmed through in vivo corneal uptake study and susceptibility test.

2. Materials and methods

2.1. Materials

FTN was a gift from Andalous Pharmaceutical Co. (Cairo, Egypt). Span 80, cholesterol, methanol (HPLC grade), dialysis membranes (typical molecular weight cutoff 14,000Da) and Rhodamine B were purchased from Sigma Chemical Company. Ethanol (95%), isopropyl alcohol, formaldehyde and stearic acid were provided from El-Nasr pharmaceutical chemicals Co. (Cairo, Egypt). All other chemicals and solvents were of analytical grade and were consumed as obtained.

2.2. Animals

Adult male albino rabbits, having an average body weight of 2±0.5 kg, were housed individually (one per cage) at 25±2 °C, with 12 hours cycle alternating of light and dark. Animals were supplied with the standard commercial food and tap water. Initial examination of all rabbits’ eyes was carried out. Rabbits with no signs of ocular inflammation were included in the study. This study was approved by Research Ethics Committee (REC), Faculty of Pharmacy, Cairo University (approval number PI 3132) and was conducted compliant with the Guide for Care and Use of Laboratory Animals published by the US National Institute of Health (NIH Publication No. 85–23, revised 2011).

2.3. Methods

2.3.1. Experimental design

FTN-loaded novasomes were formulated adopting a central composite design. This design comprises twenty trails, which are: 8 factorial points, 6 axial points and 6 replicated center point. Alpha was set at 1.68179. The studied factors were: stearic acid concentration (%) (A), span 80: drug ratio (B) and cholesterol amount (mg) (C) all at three levels. These levels were selected according to preliminary studies results and were defined as (-1, 0, +1). The studied responses were percent entrapment efficiency (EE %) (Y1), particle size (PS) (Y2), poly-dispersity index (PDI) (Y3), zeta potential (ZP) (Y4), and in-vitro release after 8 hours (Q8h) (Y5). Design-Expert® software version 7 (Stat-Ease, Inc., Minneap-olis, Minnesota, USA) was employed in order to detect the significance of the studied factors (Ahmed et al., 2020). Central composite design with levels of independent variables and their corresponding responses are presented in Table 1.

2.3.2. Formulation of FTN-loaded novasomes

Novasomes of FTN were prepared utilizing ethanol injection method (Mosallam et al., 2021) with minor adjustment. In brief, FTN (10mg), varying amount of stearic acid, span 80 and cholesterol were accurately weighted and dissolved in (10mL) ethanol using water bath at 60°C. Afterwards, the ethanolic solution was injected gradually into a four-fold
greater volume of phosphate-buffered saline (PBS, pH 7.4) magnetically stirred at the same temperature until total vaporization of ethanol. The sudden turbidity indicated the formation of novasomes, the resulted novosomal dispersions were sonicated for 15 min at 25 ± 2°C for size reduction and stored till further use at 4°C (Al-Mahallawi et al., 2014). Table 2 presents the composition of the fabricated FTN-loaded novasomal formulae (T1–T20) listed in random order.

### 2.3.3. In vitro characterization of the prepared FTN-loaded novasomes

#### 2.3.3.1. Percent entrapment efficiency (EE %)

Percent entrapment efficiency (EE %) of FTN was calculated by indirect measurement of free FTN (unentrapped FTN) (Abdelbary & AbouGhaly, 2015). Briefly, 1 mL of resulted formula was exposed to centrifugation via a cooling centrifuge (3K30, & AbouGhaly, 2015). Briefly, 1 mL of resulted formula was exposed to centrifugation via a cooling centrifuge (3K30, Sigma, Germany) at 21,000 rpm for 1 hour at 4 °C. The clear supernatant was isolated and diluted. The concentration of unentrapped FTN was spectrophotometrically assessed (Shimadzu, model UV-1601 PC, Kyoto, Japan) at λmax 252 nm using the calibration curve (n=3, R²= 0.9998). The EE % was calculated applying the following equation (Sayed et al., 2020):

\[
EE\% = \frac{\text{total amount of FTN} - \text{total amount of free FTN}}{\text{total amount of FTN}} \times 100
\]

Total amount of FTN is the real weighed quantity, total amount of free FTN (quantity of FTN in supernatant)

#### 2.3.3.2. Particle size (PS), poly-dispersion index (PDI) and Zeta-potential (ZP)

The resulted dispersions were diluted 10 times with distilled water in order to clarify their PS, PDI, and ZP. The determination was completed by light scattering based on laser diffraction employing Malvern Zetasizer (Model ZEN3600, Malvern Instruments Ltd. Worcestershire, UK) (Abdel-Elsalam & ElKasabgy, 2019).

#### 2.3.3.3. In vitro release studies

In vitro release of FTN from the formulated FTN-loaded novasomal dispersions were determined using bag dialysis method (typical molecular weight cutoff 14,000 Da; Sigma-Aldrich Co.) (Elsayed & Sayed, 2017). Concisely, dialysis membrane was soaked overnight in the release medium (phosphate buffer saline solution (pH 7.4) containing 25% ethanol to maintain the sink condition) (Albash et al., 2021; Rathod et al., 2017). Then, a dialysis bag enclosing 2 mL (equivalent to 0.5 mg of FTN) of each formula or FTN suspension was placed in 25 mL release medium in amber bottles. After that, the bottles were placed in shaker operating at 37 ± 0.5°C and 100 rpm. Aliquots of 3 mL were withdrawn at planned time intervals (0.5, 1, 2, 4, 6, 8 h) and replaced with similar volume of fresh release medium in an attempt to sustain sink condition. The percent released was calculated by spectrophotometric measurement at λmax 252 nm against the calibration curve (R²= 0.9992). All

### Table 1.

| Factor (independent variable) | Level | Response (dependent variable) | Desirability constraints |
|-------------------------------|-------|-------------------------------|--------------------------|
| A: stearic acid concentration (%) | -1 | Y1: EE % | Maximize |
| B: span 80: drug ratio | 3:1 | Y2: PS (nm) | Minimize |
| C: cholesterol amount (mg) | 20 | Y3: PDI (Mean +SD) | Minimize |
| Y4: ZP (absolute value) (mV) | | Y4: Q8h (%) | >80% |
| Y5: Q8h (%) | | | |

**Abbreviations:** EE %, percent entrapment efficiency; PDI, poly-dispersion index; PS, particle size; Q8h, percent drug released after 8 hours; ZP, zeta potential.

### Table 2.

| Trial | A: stearic acid concentration (%) | B: span 80: drug ratio | C: cholesterol amount (mg) | Y1: EE % (Mean +SD) | Y2: PS (nm) (Mean +SD) | Y3: PDI (Mean +SD) | Y4: ZP (mV) (Mean +SD) | Y5: Q8h (%) (Mean +SD) |
|-------|---------------------------------|------------------------|---------------------------|---------------------|------------------------|---------------------|------------------------|------------------------|
| T1 | 0.040 | 6:1 | 40 | 88.89 ± 1.18 | 205.45 ± 2.76 | 0.13 ± 0.00 | 80.78 ± 2.83 |
| T2 | 0.125 | 9:1 | 60 | 95.33 ± 2.16 | 301.45 ± 15.06 | 0.40 ± 0.12 | 84.81 ± 2.79 |
| T3 | 0.125 | 6:1 | 20 | 82.64 ± 2.36 | 160.40 ± 2.12 | 0.36 ± 0.06 | 95.10 ± 1.21 |
| T4 | 0.125 | 20 | 90.28 ± 2.55 | 214.60 ± 0.85 | 0.11 ± 0.01 | −50.70 ± 2.12 | 89.21 ± 1.45 |
| T5 | 0.250 | 6:1 | 40 | 90.76 ± 1.47 | 238.05 ± 3.32 | 0.16 ± 0.00 | 87.68 ± 1.75 |
| T6 | 0.375 | 6:1 | 60 | 96.53 ± 2.16 | 301.45 ± 15.06 | 0.40 ± 0.12 | 84.81 ± 2.79 |
| T7 | 0.375 | 20 | 84.72 ± 1.57 | 170.25 ± 2.90 | 0.25 ± 0.03 | −44.15 ± 0.35 | 93.61 ± 3.05 |
| T8 | 0.375 | 9:1 | 20 | 86.67 ± 1.77 | 314.80 ± 31.54 | 0.45 ± 0.45 | 92.92 ± 0.71 |
| T9 | 0.375 | 9:1 | 60 | 97.08 ± 3.54 | 323.65 ± 4.60 | 0.07 ± 0.02 | 80.87 ± 2.93 |
| T10 | 0.460 | 6:1 | 40 | 97.92 ± 0.79 | 288.65 ± 5.87 | 0.42 ± 0.03 | 80.78 ± 2.83 |
| T11 | 0.125 | 6:1 | 40 | 90.76 ± 1.47 | 205.45 ± 2.76 | 0.13 ± 0.00 | 80.78 ± 2.83 |
| T12 | 0.250 | 9:1 | 60 | 88.89 ± 1.18 | 205.45 ± 2.76 | 0.13 ± 0.00 | 80.78 ± 2.83 |
| T13 | 0.250 | 3:1 | 40 | 97.92 ± 0.79 | 288.65 ± 5.87 | 0.42 ± 0.03 | 80.78 ± 2.83 |
| T14 | 0.250 | 3:1 | 60 | 90.97 ± 0.79 | 286.15 ± 14.64 | 0.56 ± 0.02 | 85.99 ± 0.81 |

**Abbreviations:** EE %, percent entrapment efficiency; PDI, poly-dispersion index; PS, particle size; Q8h, percent drug released after 8 hours; ZP, zeta potential.
release profiles were fitted to zero, first, and Higuchi diffusion models. The largest coefficient (R²) suggests the appropriate model (Ahmed et al., 2021).

2.3.4. Selection of the optimum formula

Design-Expert® software version 7 (Stat-Ease, Inc., Minneap-olis, Minnesota, USA) was employed using numerical optimization to detect desirability regarding the significant factors and ignoring the non-significant ones. Selection was based in terms of highest EE % and ZP (as absolute value), ignoring the non-significant ones. Selection was based in terms of highest EE % and ZP (as absolute value), ignoring the non-significant ones. Selection was based in terms of highest EE % and ZP (as absolute value), ignoring the non-significant ones. Selection was based in terms of highest EE % and ZP (as absolute value), ignoring the non-significant ones. Selection was based in terms of highest EE % and ZP (as absolute value), ignoring the non-significant ones.

2.3.5. In vitro characterization of the optimum formula

2.3.5.1. Differential scanning calorimetry (DSC).

At the beginning, the optimum formula was freezed at (-20°C) followed by lyophilization at (-45°C) under lowered pressure for (24h) using freeze-dryer (Novalypse-NL 500 freeze-dryer, Savant Instruments, NY, USA) (Sayed et al., 2018). A specified weight (2mg) of FTN, stearic acid, cholesterol, lyophilized FTN-loaded optimum formula and lyophilized FTN-free optimum formula were heated to (350°C) in a nitrogen environment in an aluminum pan at a scanning rate of (10°C/min) in order to obtain their thermal characters. Thermograms were noted using DSC7 (Perkin-Elmer, Waltham, MA) (Younes et al., 2018).

2.3.5.2. Fourier transform infrared spectroscopy (FTIR).

FTIR spectra of FTN, stearic acid, cholesterol, lyophilized FTN-loaded optimum formula and lyophilized FTN-free optimum formula were recorded using FTIR spectrophotometer (model 22, Bruker, Coventry, UK). About 2-3mg of each sample was blended with dry potassium bromide and squeezed into disk ahead of being examined in the range of 4000 – 500 cm⁻¹ at 25 ± 2°C (Younes et al., 2018).

2.3.5.3. Transmission electron microscopy (TEM).

The optimum formula was imaged by TEM in order to detect its size and shape. Firstly, samples were diluted ten times with distilled water. Then, placed over carbon coated copper rods, dried at 25 ± 2°C and then, stained by 2% w/v copper rods, dried at 25 ± 2°C and then, stained by 2% w/v phosphotungstic acid. Images were taken by TEM (JEOL, Tokyo, Japan) operated at an accelerating voltage of 100kV (Sayed et al., 2018).

2.3.5.4. pH measurement.

pH determination is significant to guarantee both safety and efficacy of the optimum formula. Generally, acidic (pH < 4) or alkaline (pH > 10) solution would harm the eye (Said et al., 2021), while pH from 4 to 8 would considerably improve ocular permeation (Mohanty et al., 2013). Usually, pH of ocular preparations has a range from 3.5 to 8.5. The pH of the optimum formula was determined using a pH meter (model-3505, Jenway, Staffordshire, UK). The obtained results were the averages of triplicates ± SD (Fahmy et al., 2021).

2.3.5.5. Effect of short-term storage.

Short-term storage study is important to ensure the capability of ocular products to maintain their properties and activity after storage under certain conditions (Albash et al., 2021). The optimum formula was preserved at a storage temperature range of (4–8°C) for three months. At the end of storage period, Reevaluation of the stored optimum dispersion formula was done regarding physical appearance, EE %, PS, ZP and Q8h compared to the freshly prepared formula (Fahmy et al., 2021; Al-Mahallawi et al., 2017). EE %, PS, ZP were compared utilizing one-way ANOVA analysis. However, the release profiles of the fresh and stored optimum formula were compared using the Similarity factor “f₂”. Similarity factor “f₂” was calculated by applying the following equation (Sayed et al., 2021; Sayed et al., 2020):

\[ f_2 = 50 \log \left(1 + \frac{1}{n} \sum_{i=1}^{n} \left(R_i - T_i\right)^2 \right)^{0.5}.100 \]  

Equation (2)

R_i and T_i are the % FTN released from the fresh and stored optimum formula correspondingly at time t. The release profiles are similar when “f²” value lies between 50 and 100 (Abdelbary et al., 2016).

2.3.5.6. Effect of gamma sterilization.

The optimum formula was subjected to gamma sterilization in the presence of dry ice to avoid any unwanted effect due to the elevation of temperature after gamma irradiation. Irradiation was performed using Cobalt-60 irradiator at rate of 1.774 kGy/h. Radiation dose was 25 kGy in an Indian Gamma cell (Sayed et al., 2020). Following gamma sterilization, the optimum formula was reasessed for its appearance, EE %, PS and ZP. EE %, PS, ZP were compared utilizing one-way ANOVA analysis. The release profiles before and after gamma sterilization were compared using the previously mentioned Similarity factor “f₂” equation. R_i and T_i are the % FTN released from the optimum formula before and after gamma sterilization correspondingly at time t. The release profiles are similar when “f²” value lies between 50 and 100 (Abdelbary et al., 2016).

2.3.5.7. Minimum inhibitory concentration (MIC) determination.

The measurement of MIC was conducted using “Broth Microdilution Technique” according to the Clinical and Laboratory Standards Institute guidelines (Humphries et al., 2018). A volume of 150 μL of two fold strength Sabouraud dextrose broth (SDB) was added to each well of a sterile U-shaped bottom 96-well plate. Also 150 μL of each of the tested formulae (FTN suspension and the optimum formula) was added to the first well of each row. Two-fold serial dilutions of each of the tested formulae were done from one row to the next one till reaching the tenth row (250–0.49 μg/mL). The wells were then inoculated with 10 μL of Candida albicans ATCC 60193 suspension (10⁷ CFU/mL). Each row included one well as a negative control for sterility (neither yeast nor tested formula was placed) and another well as a positive control for growth (inoculated with yeast suspension only). Plates were incubated at 25 ± 2°C for 24 hours in aerobic environment. The lowest concentration showing no observable microbial growth was the MIC. The experiment was repeated in three independent times (Albash et al., 2021).

2.3.6. Ex vivo characterization of the optimum FTN-loaded novasomes

2.3.6.1. Ex vivo corneal permeation.

The study procedure was approved by Research Ethics Committee, Faculty of Pharmacy, Cairo University (REC-FOPCU) with a number of PI 3132. Male albino rabbits (weight 2 ± 0.5 kg) were selected for the investigation after anesthetizing them by intramuscular
injection of 35 mg/kg ketamine and 5 mg/kg xylazine (Elsayed & Sayed, 2017; Emad Eldeeb et al., 2019; Sayed et al., 2020). Afterwards, decapitation was done to isolate the cornea and sclera that were washed using PBS (pH 7.4) and directly attached to one end of the open ended tube. The receptor medium was composed of 15 mL of phosphate buffer saline solution (pH 7.4) containing 25% ethanol to maintain sink condition. The Donor medium (either the optimum formula or FTN suspension) containing an equivalent amount of 0.5 mg of FTN was used. Aliquots of 0.5 mL were withdrawn at intervals of (1, 2, 4, 6, 8, 10 h) and replaced rapidly with fresh receptor medium to preserve sink condition (Sayed et al., 2020). The gathered samples were clarified using 0.45 μm membrane filter at each time and examined by HPLC (Shimadzu, Tokyo, Japan) operated with RP-C18 column (250×4.6 mm, 5 μm) and UV detector at λmax (252 nm). The mobile phase consisted of methanol-water (85:15; v/v) at a flow rate of 1.2 mL/min. The injection volume was 20 μL. The mobile phase was filtered through 0.45μm membrane filter then 10 min sonication before running (Silva, 2019). The amount of FTN permeated per unit area (μg/cm²) was plotted versus time (h). Cumulative amount of FTN permeated through the corneal membrane per unit area $Q_{\text{inh}}$ of drug suspension (Jmax, n) was calculated for both optimum formula and drug suspension. Enhancement ratio was calculated for the optimized formula compared to the drug suspension. All studies were done in triples. The flux ($J_{\text{max}}$) and the enhancement ratio (ER) were assessed from the following equations (Abdelbary et al., 2016; Younes et al., 2018; Sayed et al., 2018; Sayed et al., 2020):

$$J_{\text{max}} = \frac{\text{Amount of drug permeated}}{\text{Time} \times \text{Area}} \quad (\text{Eq. 3})$$

$$\text{ER} = \frac{J_{\text{max}} \text{of formulation}}{J_{\text{max}} \text{of drug suspension}} \quad (\text{Eq. 4})$$

### 2.3.7.2. In vivo corneal tolerance

#### 2.3.7.2.1. Ocular irritancy test. 
This test was achieved to validate the safety of the optimum formula. Any probable optical irritancy and/or destructive consequences of the optimum formula was estimated by detecting any redness, tenderness or boosted tear formation after application to the eyes of albino rabbits. The test was conducted on three albino rabbits. The experiment was achieved by a single instillation of the tested preparation (optimum FTN-loaded formula) into one eye, while the contralateral eye functioned as control. Both eyes of the rabbits under test was examined for any sign of irritation, such as conjunctival corneal edema and/or hyperemia upon direct visual observation using a slit lamp, before treatment and at 1, 8 and 24 h following drug instillation (Abdelbary et al., 2017).

#### 2.3.7.2.2. Ex vivo corneal hydration level.
Instantaneously after the ex vivo permeation study, each cornea was detached, washed to remove any surface-remained formula, softly wiped with a filter paper to eradicate excess water and then weighed to determine wet corneal weight ($W_{\text{w}}$). Then, the cornea was dehydrated at 50°C for 24 h and reweighed to determine dry corneal weight ($W_{\text{d}}$). The corneal hydration levels (HL%) of the optimum formula and FTN suspension were compared using one-way ANOVA test. HL% was determined using the following equation (Moustafa et al., 2017):

$$\text{HL} \% = \left[1 - \frac{W_{\text{d}}}{W_{\text{w}}} \right] \times 100 \quad (\text{Eq. 5})$$

### 2.3.7.3. In vivo corneal uptake.
The drug FTN in the optimum formula was substituted by Rhodamine B (RhB) in concentration of 0.1% w/w to be examined under Confocal laser scanning microscopy (CLSM) (LSM 710; Carl Zeiss, Jena, Germany). One drop of RhB-loaded formula (100 µL) was applied into the right eye male albino rabbit (2–3 kg), while the left eye received RhB-loaded aqueous solution (negative control). After 6 h, the animals were sacrificed by decapitation after being anesthetized. The clear corneas were carefully removed and cleaned. Corneal tissues were preserved in 10% v/v formalin saline solution till assessment. Solid paraffin cubes enclosing the corneas were obtained by immersing the corneas in molten paraffin, followed by cooling. Thin slices were obtained using a microtome. Eosin and hematoxylin were used as staining agents. A digital light microscope (Leica, Cambridge, UK) was used for the examination of the specimens (Sayed et al., 2021; Sayed et al., 2020).

### 2.3.7.4. Susceptibility test.
Six rabbits were divided randomly into 2 groups (3 rabbits in each group, n = 3) where group I received the optimum formula and group II received FTN suspension. Candida albicans ATCC 60193 was used as the test organism. The experiment was performed as described by Basha et al (Basha et al., 2013) but with slight modifications. Briefly, fifty microliters of each of the tested formulae (the optimum formula and FTN suspension) were inserted within the lower conjunctival sac of the right eye of the rabbit using a micropipette. No drug was inserted in the left eye of each rabbit to serve as the control. At specific time intervals (1–10 hours), four sterile filter paper disks (Whatman no. 5, 6 mm in diameter) were wetted by placing the disks under the eyelid of the eye of each rabbit. For each eye (right and left), two disks were put in an Eppendorf tube (1.5 mL) which contains 500 μL Sabouraud dextrose broth (SDB) inoculated with 10% v/v yeast suspension (107 CFU/mL). The other
two disks were put in an Eppendorf tube containing 500 μL uninoculated SDB; this was used as a blank during measuring the optical densities. Afterwards, aerobic incubation of all the tubes was carried out at 25 ± 2°C for 24 hours. After incubation, 200 mL of each tube was transferred to sterile 96-well plates and the optical densities (OD$_{600nm}$) were measured using an automated spectrophotometric plate reader (Biotek, Synergy 2, USA) at a single wavelength of 600 nm. The obtained results were presented as average percentage growth inhibition (mean ± standard deviation).

The growth inhibition % was calculated using the following equation (Abdelbary et al., 2016; Fahmy et al., 2021):

\[
\text{Growth inhibition } \% = \frac{\text{Control Left Eye (OD$_{600nm}$)} - \text{Test Right Eye (OD$_{600nm}$)}}{\text{Control Left Eye (OD$_{600nm}$)}} \times 100
\]

(Eq. 6)

The area under the curve from 1 to 10h (AUC$_{1-10h}$) was calculated from the curve of each individual animal using GraphPad Prism 7 software. Student’s t-test was used to compare between the optimum formula and FTN suspension.

2.3.8. Statistical analysis

Analysis of central composite design was performed using Design-Expert software version 7 (Stat-Ease Inc., Minneapolis, USA) (Ahmed et al., 2021). All measurements were done in triplicates. Results were represented as mean ± standard deviation (SD) and compared using ANOVA test ($p < 0.05$ indicated significance). One-way ANOVA was used for two independent groups comparisons were appropriate.

3. Results and discussions

3.1. Analysis of central composite design

The effects of stearic acid concentration (g%) (A), span 80: drug ratio (B) and cholesterol amount (mg) (C) as the independent variables on the different responses of the prepared FTN-loaded novasomes were determined using central composite design (Ahmed et al., 2021). Testing of each response was done exclusively and fitted to the model having highest prediction $R^2$ (Zhang et al., 2010). The predicted $R^2$ values were in reasonable synchronization with the adjusted $R^2$ for all the studied responses as shown in Table 3.

3.1.1. Model analysis of EE %

The ability of the formulated novasomes to entrap considerable quantity of FTN is crucial for its potential use as an ocular delivery system (Abdelbary et al., 2016). EE % varied between (78.47 ± 0.98 and 97.92 ± 0.79%), as presented in Table 2. ANOVA analysis revealed that factor A (stearic acid concentration (%)), factor B (span 80: drug ratio) and factor C (cholesterol amount (mg)) had a positive significant effect ($p < 0.05$). The effects of all factors are graphically explained in Figure 1(a). The resulting equation in terms of coded factors was as follows:

\[
\text{EE } \% = 90.56 + 0.74A + 1.19B + 5.58C - 0.66C^2
\]

Figure 1. Response-plots for the effect of Factor A: stearic acid concentration (%), Factor B: span: drug ratio and Factor C: cholesterol amount (mg) on (a) EE%, (b) PS, (c) ZP and (d) Q8h (%).
Considering factor A ($p=0.0001$), stearic acid is a saturated free fatty acid (FAA) with wide application because of its safety (Singh et al., 2020). Its positive significant effect could be explained on the basis of increasing the hydrophobicity of the medium which is favorable to the hydrophobic FTN (Ahmad et al., 2019). Hydrophobicity of stearic acid arises from its long alkyl chain (C18) along with its saturation reflecting in high phase transition temperature ($T_c=69 \degree C$), leading to the formation of less leaky vesicles resulting in higher EE%. Regarding factor B ($p<0.0001$), increasing ratio or concentration of span 80 having low HLB (4.3) (Ruckmani & Sankar, 2010) due to its long alkyl chain of oleate moiety(C18) (Abdelbary et al., 2017), resulting in less hydrophilic holes and reducing the fluidity of the membrane by reducing the bilayers amphiphilic property (Abdelbari et al., 2021). Moreover, it was found that the EE% value increases upon increasing surfactant concentration which could be attributed to the added emulsification and stabilization impact of the lipid material in the presence of high surfactant concentration (Abdelbary & Fahmy, 2009). Finally, increasing the concentration of surfactant resulted in increasing the amount of the formed novasomes and subsequently the volume of the hydrophobic bilayer that acts as housing domain of the hydrophobic drug FTN (El-Laithy et al., 2011). Regarding Factor C ($p<0.0001$), as the concentration of cholesterol increases, the permeability of the bilayers membrane decreases with increasing membrane rigidity resulting in high entrapment of the lipophilic drug within the bilayers (Abdelbary et al., 2017; Emad Eldeeb et al., 2019).

### 3.1.2. Model analysis of PS

Nano-sized drug delivery systems could enhance corneal permeation and extend their efficacy (Dai et al., 2013). PS varied from (124.35±0.92 to 338.95±25.95 nm) as presented in Table 2. ANOVA analysis showed that factor A (stearic acid concentration (%)), factor B (span 80: drug ratio) and factor C (cholesterol amount (mg)) had a positive significant effect ($p<0.05$). The effects of all factors are graphically explained in Figure 1(b). The resulting equation in terms of coded factors was as follows:

$$PS = 237.68 + 16.62A + 66.92B + 12.79C$$

Considering factor A ($p=0.0138$), stearic acid is a FAA with high melting point (69°C) which leads to greater melting viscosity and subsequently reducing the efficacy of sonication in decreasing PS. Also, there is a direct association between the PS and the formerly stated increase in the EE%, since entrapping large quantities of FTN results in increasing the distance between the bilayers, consequently PS increases (Ahmed et al., 2020; Hathout et al., 2007). Therefore increasing the concentration of stearic acid, span 80 (factor B, $p<0.0001$) or cholesterol (factor C, $p=0.0493$) will lead to more entrapment of the hydrophobic FTN within the bilayers as previously discussed in model analysis of EE % resulting in increasing the PS (Mosallam et al., 2021). The effect of factor C might be also explained in terms of the amphiphilic nature of cholesterol. The cholesterol intercalates inside the bilayer by placing the polar head toward the hydrophilic surface and the aliphatic chain parallel to the surfactant alkyl chains, accordingly PS increased (Emad Eldeeb et al., 2019).

### 3.1.3. Model analysis of PDI

With regard to PDI, a value of 0 indicates homogenous system, while a value of 1 indicates highly heterogeneous system (Ahmed et al., 2020; Abdelbari & Aburahma, 2015). PDI of all the prepared formulae fluctuated between (0.06±0.01 to 0.56±0.02) as presented in Table 2. These results confirmed the proper uniformity of the prepared FTN-loaded formulae. ANOVA analysis revealed that all factors had a non-significant effect ($p>0.05$) on PDI. So it was excluded from optimization criteria.

### 3.1.4. Model analysis of ZP

Zeta potential (ZP) gives an indication about the stability of the nano-system as it represents the overall charges obtained by colloidal dispersion. As a general rule, the system with ZP around ±30 is considered stable due to the presence of electric repulsion between particles (Muller et al., 2001). Results of Zeta potential values ranged from (-29.45±1.91 to -83.30±0.57) as shown in Table 2, clarifying that all formulae had enough charge to avoid accumulation of particles. ANOVA analysis showed that factor A (stearic acid concentration (%)), factor B (span 80: drug ratio) and factor C (cholesterol amount (mg)) had a positive significant ($p<0.05$) effect on ZP. The effects of all factors are graphically explained in Figure 1(c). The resulting equation in terms of coded factors was as follows:

$$ZP = 54.04 + 3.78A + 3.05B + 14.00C$$

It was detected that the absolute ZP value increases upon increasing amount of stearic acid, surfactant or cholesterol. Stearic acid (factor A, $p=0.0017$) has free carboxylic acid group ($C_{17}H_{35}COOH$). However, span 80 (factor B, $p=0.0076$) and cholesterol (factor C, $p<0.0001$) have free hydroxyl groups in their chemical structure ($C_{24}H_{44}O_6$ and $C_{27}H_{46}O_8$ respectively). Ionization of these groups would increase the negative charge of the resulted formulae, accordingly all factors had a positive significant effect on ZP (Emad Eldeeb et al., 2019; Zubairu et al., 2015).

### 3.1.5. Model analysis of in vitro release (Q8h)

In vitro release profiles of all the prepared formulae were accomplished against FTN suspension as control. Q8h of all the prepared formulae fluctuated between (80.78±2.83 to 95.57±2.48) as presented in Table 2. Figure 2 clarifies that the in vitro release profiles of all the prepared FTN-loaded formulae showed significantly faster release profile ($p<0.05$) more than FTN suspension. This behavior was mainly attributed to the smaller particle size of the developed
novasomes compared with the size of the pure drug suspension being coarse dispersion. Regarding ANOVA analysis, factor A (stearic acid concentration (%)) and factor C (cholesterol amount (mg)) had a negative significant effect on Q8h ($p < 0.05$), while factor B (span 80: drug ratio) had non-significant effect at Q8h ($p > 0.05$). The outcomes of these factors are shown in Figure 1(d). The resulting equation in terms of coded factors was as follows:

$$Q8h = 88.78 - 1.19A - 4.77C$$

Both factor A ($p = 0.0031$) and factor C ($p < 0.0001$) lead to increase the hydrophobicity of the constructed formula compared to the release medium, so FTN would favor to stay inside the novosomal system. Generally, the more entrapped drug the larger the vesicle size therefore the slower the release (Ahmed et al., 2020; Abdelbary & Aburahma, 2015). Also, incorporation of stearic acid and cholesterol would decrease the formation of transient hydrophilic holes and reduce the fluidity of the lipid bilayer (Abdelbary et al., 2017). It is critical to justify the biphasic release profile of the novosomal system as the early burst phase might be due to the desorption of the unentrapped FTN that presents between the large hydrocarbon chains in the lipid bilayer of novosomal system. After that, a slower phase due to the reduced fluidity of the novosomal system by stearic acid and cholesterol (Ahmed et al., 2021). Higuchi-diffusion model is the best model to justify the release profiles (highest r-square).

### 3.2. Testing the validity of optimization process

Numerical optimization showed that the composition of the optimum formula was (stearic acid concentration = 0.37%, span 80: drug ratio = 3:1 and cholesterol amount = 60 mg with desirability =0.738). The optimum formula revealed the highest EE % (94.31 ± 2.50%), and ZP (-66.95 ± 0.92 mV) (as absolute value), Q8h > 80% (85.33 ± 1.35%) and lowest PS (197.05 ± 9.97) respectively. The validity of the optimization process was guaranteed by matching the results of the observed and predicated responses regarding EE %, PS, ZP and % drug released (Q8h) as presented in Table 4. The small % deviation as absolute value verifies our models.

### 3.3. In vitro characterization of the optimum formula

#### 3.3.1. Differential scanning calorimetry (DSC)

DSC thermograms of FTN, stearic acid, cholesterol, lyophilized FTN-loaded optimum formula and lyophilized FTN-free optimum formula are presented in Figure 3. FTN revealed an endothermic peak at 135°C that is related to its melting point (Kim et al., 1989; Albash et al., 2020). Stearic acid thermogram showed an endothermic peak at 55°C (HariPrasad D et al., 2020). Cholesterol thermogram showed an endothermic peak at 38°C and 149°C related to its solid phase transition and melting point respectively (Jin et al., 2013). It is obvious that the disappearance of the characteristic melting peak of FTN certifies the total entrapment of FTN inside the novasomes (Shamma et al., 2019) and that FTN exists in its amorphous state (Albash et al., 2019).

| Table 4. The optimum formula characterization. |
|------------------------------------------------|
| Response | Y1 | Y2 | Y4 | Y5 |
|----------|----|----|----|----|
| EE %     | 94.31 ± 2.50% | PS (nm) | 197.05 | ZP (mV) | -66.95 ± 0.92 mV |
| PS       | 197.05 | 200.16 | -68.76 | Q8h (%) | 85.33 |
| ZP       | -66.95 ± 0.92 mV | 2.63 | 3.03 |
| % Deviation (absolute) | 0.75 | 1.55 | 2.63 | 3.03 |

**Abbreviations:** EE %, percent entrapment efficiency; PS, particle size; Q8h, percent drug released after 8 hours; ZP, zeta potential.
3.3.2. Fourier transforms infrared spectroscopy (FTIR)
Figure 4 shows the FTIR spectra of FTN, stearic acid, cholesterol, lyophilized FTN-loaded optimum and lyophilized FTN-free optimum formula. FTN has a certain structure similarity with chlorinated imidazole compounds (Castro et al., 2016). The FTIR spectra of FTN are shown at 1581.63 cm\(^{-1}\) corresponding to C=N stretching, other peaks appeared at 1469.76 cm\(^{-1}\) (C=C aromatic stretch), 1091.71 cm\(^{-1}\) (C-O-C ether stretch) and 794.67 cm\(^{-1}\) (C-Cl stretch). The characteristic peaks of stearic acid are revealed at 2916.37, 2850.79 cm\(^{-1}\) (-CH\(_2\)-) and 1701.22 (-COOH) (Zhu et al., 2016). The specific peaks of cholesterol are found at 3417.86 (-OH), in addition to bands between 2800–3000 cm\(^{-1}\) due to asymmetric and symmetric stretching of CH\(_2\) and CH\(_3\) groups respectively (Gupta et al., 2014). Disappearance of FTN characteristic peaks from the spectra of FTN-loaded optimum formula signifies the complete entrapment of the FTN inside the formula confirmed by the outcomes of DSC (Ahmed et al., 2020; Sayed et al., 2018).

3.3.3. TEM microscopy
Morphological evaluation of the optimum formula is presented in Figure 5. TEM provides a verification of the outcomes of Malvern particle size analyzer. PS from optimum formula measured in triplicates was (197.05 ± 9.97). TEM proved that particles were almost spherical, non-aggregated with a smooth surface and narrow size.

3.3.4. pH measurement
pH of the optimum formula was 7.29±0.05, ensuring the appropriateness of its ophthalmic use (pH of tears = 7.4) (Sayed et al., 2021; Fahmy et al., 2021). pH of the optimum formula also augments its efficacy since pH from 4 to 8 would considerably improve ocular permeation (Mohanty et al., 2013).

3.3.5. Effect of short-term storage
At the end of the experiment, the stored vesicles did not show any clumps or changes in their physical appearance. Results of EE %, PS and ZP for fresh and stored optimum formula (3 months) are shown in Table 5. Non-significant differences (p>0.05) were found in EE %, PS, ZP. The similarity factor (f\(_2\)) was equal to 87.15, indicating similar in vitro release profiles (Diaz et al., 2016). These results emphasize the high stability nature of the optimum formula which could be as a result of its high negative charge (-66.95 ± 0.92 mV) that will prevent any aggregation or agglomeration of the stored vesicles (Harisa & Badran, 2015). In addition to, the small PS of the optimum formula would result in large surface area for the ionizable groups to expose their charge at the surface of the formed novasomes.
3.3.6. Effect of gamma sterilization
Sterilization of ophthalmic dosage forms is essential to prevent co-infecting the patients with dangerous microbes and is less risky than aseptic processing (Sayed et al., 2021; Younes et al., 2018). No observable change in the physical appearance after gamma sterilization was detected. Moreover, EE%, PS and ZP values did not alter significantly when matched to the unsterilized control (p > 0.05), as presented in Table 5. The similarity factor (ƒ2) was equal to 77.94, indicating similar in vitro release profiles (Diaz et al., 2016). These results indicate that gamma sterilization will not harm the optimum formula and can be used safely as sterilization technique.

3.3.7. Minimum inhibitory concentration (MIC) determination
The antifungal activity of the optimum formula and FTN suspension were evaluated in-vitro using Candida albicans ATCC 60193 as the tested organism (Albash et al., 2021). MIC for the optimum formula was found to be equal to 62.5 µg/mL while that for FTN suspension was higher than 500 µg/mL. The optimum formula showed more than 3 times higher antifungal activity than that of FTN suspension which might be due to the lower particle size and higher zeta potential values. Small PS would result in longer residence time and enhanced drug permeability. ZP affects the interaction of the formed system with the negatively charged microbial cell surface. Patil et al., proposed the existence of few cationic sites for nonspecific adsorption of the negatively charged particles in the form of clusters as a result of their repulsive interactions with the large negatively charged domains of the cell surface. Moreover, the adsorbed particles create a lowered charge density that may support adsorption of other free particles. Thus, the enhanced cellular uptake of negatively charged nanoparticles resulted from the nonspecific adsorption and formation of nanoparticles clusters (Patil et al., 2007). These results conform with previous studies where the PS and ZP significantly influenced the antifungal activity of the tested drugs (Ing et al., 2012). Finally, improved permeation of the optimum formula will exert higher antifungal activity leading to a lower MIC compared to FTN suspension.

3.4. Ex vivo characterization of the optimum FTN-loaded formula

3.4.1. Ex vivo corneal permeation
The permeation profiles of the optimum and FTN suspension are shown in Figure 6. The optimum formula displayed improved quantity of FTN permeated after 10h (Q_{10h}\text{permeation of the optimum formula} = 527.98 ± 12.00 µg/cm²) compared to (Q_{10h}\text{permeation of FTN suspension} = 174.66 ± 6.94 µg/cm²). The optimum formula showed superior flux (J_{max}\text{of the optimum formula} = 52.80 ± 1.20 µg/cm²/h) compared to (J_{max}\text{ of FTN suspension} = 17.47 ± 0.69 µg/cm²/h). One-way ANOVA showed that the optimum formula had significantly higher amount permeated after 10h and flux compared to FTN suspension. The enhancement ratio of the optimum formula was 3.02. These results emphasize higher permeation of FTN from the optimum formula. The superior
permeation results of the prepared novasomes might be due its small PS which increase the residence time and facilitates the passage through the hydrated network of the corneal stroma (Younes et al., 2018; Mosallam et al., 2021). The presence of stearic acid also contributes to better permeation since saturated fatty acids with high melting point had an improved permeation rate across the biological membranes. FFA can incorporate rapidly into the lipid membrane and increase the curvature stress that results in formation of lipid instabilities and enhancing its permeability (Singh et al., 2020). Moreover, cholesterol acts as penetration enhancer that facilitates the diffusion of the formed novasomes (Emad Eldeeb et al., 2019). Finally, surfactants could improve the permeation by loosening the tight junctions of the corneal epithelium (Younes et al., 2018).

3.4.2. Ex vivo corneal hydration level
The corneal hydration level (HL%) was calculated to estimate the injury initiated to the corneal tissues after the ex vivo permeation study. HL% of the normal healthy cornea is between (76–80%) (Huang et al., 2017). HL% of the optimum formula and FTN suspension were found to be equal to (78.50 ± 0.37 and 79.25 ± 0.48 respectively). One-way ANOVA test revealed absence of significant difference (p > 0.05) in % HL obtained from the optimum formula and FTN suspension. Consequently, the optimum formula could be counted safe and non-harmful to the eye (Moustafa et al., 2017).

3.5. In vivo characterization of the optimum FTN-loaded formula

3.5.1. Ocular irritancy test
Results of this test showed that the optimum formula did not display any sign of redness, inflammation or increased tear production for 24 h. Consequently, the optimum FTN-loaded novasomes could be considered tolerable and non-irritant to the eye (Abdelbary et al., 2017).

3.5.2. In vivo corneal tolerance
Considering corneal tissues exposed to normal saline as negative control; no histopathological change with normal histological structure of the covering lining epithelial cell layer, the underlying stroma, and the last layer of the endothelium, as shown in Figure 7(a). Regarding corneal tissues exposed to isopropyl alcohol as positive control; deformed and separated epithelial layers were detected, as shown in Figure 7(b). Considering corneal tissues exposed to the optimum formula; no histopathological modification in the cornea, iris, retina, or sclera, as shown in Figure 7(c). As a conclusion, the optimum FTN-loaded novasomes are considered safe be applied to the eye without any injuring or inflammation consequences (Sayed et al., 2020).

3.5.3. In vivo corneal uptake
To study the ability of the optimum formula to enhance the corneal permeation of FTN, CLSM was employed to detect the transcorneal behavior of RhB-loaded formulae after instillation, by tracing fluorescence signals inside the corneal tissues. Upon examining CLSM micrographs, it is clear that the RhB-loaded optimum formula demonstrated greater penetration (90 μm) than RhB-loaded aqueous solution (27 μm), as shown in Figure 8. This fits with the findings of earlier ex vivo permeation study. Carrying the antifungal drug (FTN) into the stromal layer providing a good treatment option for deep fungal infections (Younes et al., 2018).

3.5.4. Susceptibility test
The optimum formula and FTN suspension were evaluated in vivo using Candida albicans ATCC 60193 as the test organism. Percentage of growth inhibition of Candida albicans was related to the drug’s retention time on the eye surface following the administration, as shown in Figure 9. Growth inhibition percentage of the optimum formula reached the maximum (72.77 ± 13%) two-hours post-administration and then decreased gradually. On the other hand, the FTN suspension reached a maximum of 30.83 ± 8.8% one-hour post-administration and then showed almost constant level from the second hour until the 9th hour of the study period (27 ± 2.5% − 20.16 ± 7.02% from 2 h − 9 h). The growth inhibition percentage of the optimum formula was significantly higher than that of FTN suspension until the fifth hour post-application (Student's t-test, p < 0.05, p-value =0.019). The optimum formula significantly sustained the antifungal activity of FTN on the ocular surface for a relatively longer time with an area under the curve of about 1.6 fold higher than that of FTN suspension (AUC1h-10h = 306.5 and 190.2, respectively).

4. Conclusions
In this research, FTN-loaded novasomes were fruitfully prepared via ethanol injection technique. The optimum formula proved minute particle size (197.05 ± 9.97 nm) with spherical morphology, great percent entrapment efficiency...
(94.31 ± 2.50%), accepted zeta potential (-66.95 ± 0.92 mV), high % in vitro release (Q8h) (85.33 ± 1.35%) and high physicochemical stability. The complete entrapment of FTN inside the optimum formula was ensured by DSC and FTIR studies. Suitability of the optimum formula was proved through pH measurement, ex vivo corneal hydration level, enhanced ex vivo corneal permeation (Q10h permeation = 527.98 ± 12.00 µg/cm²) and high stability after gamma irradiation. Efficacy of the optimum formula was proved through in vitro MIC determination. Further in vivo tests including: ocular irritancy test, in vivo corneal tolerance test, in vivo corneal uptake and susceptibility test revealed the validity of FTN-loaded niosomes as a favorable method to enhance FTN ocular delivery and thereby its antifungal activity.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

The author(s) reported there is no funding associated with the work featured in this article.

References

Abdelbari MA, El-Mancy SS, Elshafeey AH, Abdelbary AA. (2021). Implementing Spanlastics for Improving the Ocular Delivery of Clotrimazole: In vitro characterization, ex vivo permeability, microbiological assessment and in vivo safety study. Int J Nanomedicine 16:6249–61.
Abdelbary AA, Abd-Elsalam WH, Al-Mahallawi AM. (2016). Fabrication of novel ultradeformable bilosomes for enhanced ocular delivery of terconazole: In vitro characterization, ex vivo permeation and in vivo safety assessment. Int J Pharm 513:688–96.
Abdelbary AA, AbuGhaly MH. (2015). Design and optimization of topical methotrexate loaded niosomes for enhanced management of
psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study. Int J Pharm 485:235–43.

Abdelbary G, Fahmy RH. (2009). Diazepam-loaded solid lipid nanoparticles: design and characterization. AAPS PharmSciTech 10:211–9.

Abdelbary GA, Aburahma MH. (2015). Oro-dental mucoadhesive proniosomal gel formulation loaded with lornoxicam for management of dental pain. J Liposome Res 25:107–21.

Abdelbary GA, Amin MM, Abdelmotealeb M. (2016). Novel mixed hydro-tropic solubilization of Zaleplon: Formulation of oral tablets and in-vivo neuropharmacological characterization by monitoring plasma GABA level. J Drug Delivery Sci Technol 33:98–113.

Abdelbary GA, Amin MM, Zakaria MY. (2017). Ocular ketoconazole-loaded proniosomal gels: formulation, ex vivo corneal permeation and in vivo studies. Drug Deliv 24:309–19.

Abd-Elsalam WH, Ibrahim RR. (2021). Span 80/TPGS modified lipid-coated chitosan nanocomplexes of acyclovir as a topical system for viral skin infections. Int J Pharm 609:121214.

Ahmad I, Pandit J, Sultana Y, et al. (2019). Optimization by design of etosopide solid loaded lipid nanoparticles for ocular delivery: Characterization, pharmacokinetic and deposition study. Mater Sci Eng C Mater Biol Appl 100:959–70.

Ahmed S, Kassem MA, Sayed S. (2020). Bilosomes as promising nanove-hicular carriers for improved transdermal delivery: Construction, in vitro optimization, ex vivo permeation and in vivo evaluation. Int J Nanomedicine 15:9783–98.

Ahmed S, Kassem MA, Sayed S. (2021). Co-polymer mixed micelles enhanced transdermal transport of Lornoxicam: in vitro characterization, and in vivo assessment of anti-inflammatory effect and antinociceptive activity. J Drug Delivery Sci Technol 62:102365.

Albash R, Al-Mahallawi AM, Hassan M, Alaa-Eldin AA. (2021). Development and optimization of terpene-enriched vesicles (terpesomes) for effective ocular delivery of fenticonazole nitrate: In vitro characterization and in vivo assessment. Int J Nanomedicine 16:6609–21.

Albash R, Elmahboub Y, Baraka K, et al. (2020). Ultra-deformable liposome-s containing terpenes (terpesomes) loaded fenticonazole nitrate for treatment of vaginal candidiasis: Box-Behnken design optimization, comparative ex vivo and in vivo studies. Drug Deliv 27:1514–23.

Albash R, El-Nabarawi MA, Refai H, Abdelbary AA. (2019). Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. Int J Nanomedicine 14:6555–74.

Albash R, Yousry C, Al-Mahallawi AM, Alaa-Eldin AA. (2021). Utilization of PEGylated cerosomes for effective topical delivery of fenticonazole nitrate: in vitro characterization, statistical optimization, and in-vivo assessment. Drug Deliv 28:1–9.

Al-Mahallawi AM, Khossehah OM, Shoukri RA. (2017). Nano-transfersomal proniosomal gel formulation loaded with lornoxicam for management of dental pain. J Liposome Res 25:107–21.

Abdelbary GA, Amin MM, Abdelmotealeb M. (2016). Novel mixed hydro-tropic solubilization of Zaleplon: Formulation of oral tablets and in-vivo neuropharmacological characterization by monitoring plasma GABA level. J Drug Delivery Sci Technol 33:98–113.

Abdelbary GA, Amin MM, Zakaria MY. (2017). Ocular ketoconazole-loaded proniosomal gels: formulation, ex vivo corneal permeation and in vivo studies. Drug Deliv 24:309–19.

Abd-Elsalam WH, Shoukry O, Mahran LG. (2011). Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies. Eur J Pharm Biopharm 77:43–55.

El-Laithy HM, Shoukry O, Mahran LG. (2011). Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies. Eur J Pharm Biopharm 77:43–55.

Elsayed I, Sayed S. (2017). Tailored nanostructured platforms for boosting transcorneal permeation: Box-Behnken statistical optimization, comprehensive in vitro, ex vivo and in vivo characterization. Int J Nanomedicine 12:7947–62.

Emad Eldeeb A, Salah S, Ghorab M. (2019). Formulation and evaluation of cubosomes drug delivery system for treatment of glaucoma: Ex-vivo permeation and in-vivo pharmacodynamic study. J Drug Delivery Sci Technol 52:236–47.

Emad Eldeeb A, Salah S, Ghorab M. (2019). Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study. Drug Deliv 26:509–21.

Fahmy AM, Hassan M, El-Setouhy DA, et al. (2021). Voriconazole ternary micellar systems for the treatment of ocular mycosis: Statistical op-timization and in vivo evaluation. J Pharm Sci 110:2130–8.

S. AHMED ET AL.

Gautdana R, Ananthula HK, Parenky A, Mitra AK. (2010). Ocular drug delivery. JAPS J 12:348–60.

Gregoridias G. (1995). Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol 13:527–37.

Gupta U, Singh V, Kumar V, Khajuria Y. (2014). Spectroscopic studies of cholesterol: Fourier transform infra-red and vibrational frequency analysis. Material Focus 3:1–7.

HairiPrasad D T, Reddy RM, Maheswari CU, Reddy E. (2020). Effect of iron scrap additives in stearic acid as PCM for thermal energy storage system. J Therm Anal Calorim 141:2497–510.

Harisa GI, Badran MM. (2015). Simvastatin nanoplpid carriers decreased hypercholesterolemia induced cholesterol inclusion and phosphati-dylserine exposure on human erythrocytes. J Mol Liq 208:202–10.

Hathout RM, Mansour S, Mortada ND, Guinedi AS. (2007). Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech 8:1.

Huang J, Peng T, Li Y, et al. (2017). Ocular cubosomes drug delivery system for timolol maleate: Preparation, characterization, cytotoxicity, ex vivo, and in vivo evaluation. AAPS PharmSciTech 18:2919–26.

Humphries RM, Ambler J, Mitchell SL, et al. (2018). CLSI methods develop-ment and standardization working group best practices for evaluation of antimicrobial susceptibility tests. J Clin Microbiol 56: e01934–17.

Imanian ME, Biglar F. (2022). Modeling and prediction of surface roughness and dimensionless accuracy in SLS 3D printing of PVA/CA com-posite using the central composite design. J Manuf Processes 75:154–69.

Ing LY, Zin NM, Sarwar A, Katas H. (2012). Antifungal activity of chitosan nanoparticles and correlation with their physical properties. Int J Biomater 2012:632698.

Jin Y, Wen J, Garg S, et al. (2013). Development of a novel niosomal system for oral delivery of Ginkgo biloba extract. UN 8:421–30.

Kaur IP, Garg A, Singla AK, Aggarwal D. (2004). Vesicular systems in ocular drug delivery: an overview. Int J Pharm 269:1–14.

Kim Y I, Kim S I, Choi J Y. Dissolution enhancement of fenticonazole nitrate from hydrophilic polymer solid dispersions. 1989 ;19:109–116.

Mohanty R, Mishra SK, Majumdar DK. (2013). Effect of formulation factors on in vitro transcorneal permeation of voriconazole from aqueous drops. J Adv Pharm Technol Res 4:210–6.
Mosallam S, Ragaie MH, Moftah NH, et al. (2021). Use of novasomes as a vesicular carrier for improving the topical delivery of terconazole: In vitro characterization, in vivo assessment and exploratory clinical experimentation. Int J Nanomedicine 16:119–32.

Moustafa MA, Elnaggar YSR, El-Refaie WM, Abdallah OY. (2017). Hyalugel-integrated liposomes as a novel ocular nanosized delivery system of fluconazole with promising prolonged effect. Int J Pharm 534:14–24.

Muller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47:3–19.

Patil S, Sandberg A, Heckert E, et al. (2007). Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials 28:4600–7.

Prausnitz MR, Noonan JS. (1998). Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci 87:1479–88.

Rathod LV, Kapadia R, Sawant KK. (2017). A novel nanoparticles impregnated ocular insert for enhanced bioavailability to posterior segment of eye: In vitro, in vivo and stability studies. Mater Sci Engin C, Mater Biol Appl 71:529–40.

Ruckmani K, Sankar V. (2010). Formulation and optimization of Zidovudine niosomes. AAPS PharmSciTech 11:1119–27.

Said M, Aboelwafa AA, Elshafeey AH, Elsayed I. (2021). Central composite optimization of oculcar mucosahesive cubosomes for enhanced bioavailability and controlled delivery of voriconazole. J Drug Delivery Sci Technol 61:102075.

Sayed S, Abdelmoteleb M, Amin MM, Khowessah OM. (2020). Effect of formulation variables and gamma sterilization on transcorneal permeation and stability of proniosomal gels as ocular platforms for anti-glaucoma drug. AAPS PharmSciTech 21:87.

Sayed S, Abdel-Moteleb M, Amin MM, Khowessah OM. (2021). Cubogel as potential platform for glaucoma management. Drug Deliv 28:293–305.

Sayed S, Elsayed I, Ismail MM. (2018). Optimization of beta-cyclodextrin consolidated micellar dispersion for promoting the transcorneal permeation of a practically insoluble drug. Int J Pharm 549:249–60.

Sayed S, Habib BA, Elsayed GM. (2018). Tri-block co-polymer nanocarriers for enhancement of oral delivery of felodipine: preparation, in vitro characterization and ex vivo permeation. J Liposome Res 28:182–92.

Shamma RN, Sayed S, Sabry NA, El-Samanoudy SI. (2019). Enhanced skin targeting of retinoic acid spanlastics: in vitro characterization and clinical evaluation in acne patients. J Liposome Res 29:283–90.

Silva TAC. (2019). Josilene; Salgado, Hérida Regina Nunes. Development of stability-indicating LC method assisted by Design of Experiment for fenticonazole cream analysis in presence of degradation product. J Basic Appl Pharmaceut Sci 40:e622.

Singh A, Yadagiri G, Parvez S, et al. (2020). Formulation, characterization and in vitro anti-leishmanial evaluation of amphotericin B loaded solid lipid nanoparticles coated with vitamin B12-stearic acid conjugate. Mater Sci Engin C, Mater Biol Appl 117:111279.

Veraldi S, Milan R. (2008). Topical fenticonazole in dermatology and gynaecology: current role in therapy. Drugs 68:2183–94.

Xu D, Li Y, Yang F, et al. (2022). Structure and transport mechanism of the human cholesterol transporter ABCG1. Cell Rep 38:110298.

Younes NF, Abdel-Halim SA, Ellassasy AI. (2018). Corneal targeted Sertaconazole nitrate loaded cubosomes: Preparation, statistical optimization, in vitro characterization, ex vivo permeation and in vivo studies. Int J Pharm 553:386–97.

Younes NF, Abdel-Halim SA, Ellassasy AI. (2018). Solutol HS15 based binary mixed micelles with penetration enhancers for augmented corneal delivery of sertaconazole nitrate: optimization, in vitro, ex vivo and in vivo characterization. Drug Deliv 25:1706–17.

Zhang Y, Wang X, Lin X, et al. (2010). High azithromycin loading powders for inhalation and their in vivo evaluation in rats. Int J Pharm 395:205–14.

Zhu J, Liu B, Li L, et al. (2016). Simple and green fabrication of super-hydrophobic surface by one-step immersion for continuous oil/water separation. J Phys Chem A 120:5617–23.

Zubairu Y, Negi LM, Iqbal Z, Talegaonkar S. (2015). Design and development of novel bioadhesive niosomal formulation for the transcorneal delivery of anti-infective agent: In-vitro and ex-vivo investigations. Asian J Pharm Sci 10:322–30.